Shanghai MicroPort MedBot (Group) Co., Ltd.
上海微创医疗机器人（集团）股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2252)

CHANGE OF DIRECTORS

The board of directors (the "**Board**") of Shanghai MicroPort Medbot (Group) Co., Ltd (the "**Company**" and its subsidiaries, collectively the "**Group**") hereby announces the following changes of members of the Board:

Resignation of Directors

Mr. Yu Liu ("**Mr. Liu**") has tendered his resignation from his position as an executive director of the Company and as a member of the commercialisation committee of the Company with effect from the date of this announcement due to the need to devote more time to other business.

Ms. Min Liang ("**Ms. Liang**") has tendered her resignation from her position as a non-executive director of the Company and as a member of the nomination committee and the commercialisation committee of the Company with effect from the conclusion of the forthcoming extraordinary general meeting ("**EGM**") of the Company due to the need to devote more time to other business.

Mr. Liu and Ms. Liang have both confirmed that they have no disagreement with the Board, and there are no matters relating to their resignations that need to be brought to the attention of the shareholders of the Company.

The Board would like to express sincere gratitude to Mr. Liu and Ms. Liang for their valuable contributions to the Company during their respective tenures of office.

Proposed Appointment of Non-Executive Directors

The Board resolved to nominate Mr. Jonathan W Chen ("**Mr. Chen**") and Ms. Qing Hui ("**Ms. Hui**") as non-executive directors of the Company. The proposed appointments of Mr.

Chen and Ms. Hui as non-executive directors of the Company are subject to consideration and approval of the shareholders of the Company at the EGM.

The biographical details of Mr. Chen and Ms. Hui are as follows:

Mr. Jonathan W Chen

Mr. Chen, aged 51, has over 29 years of experience in the medical device industry. Mr. Chen currently serves as the Rotating Chief Executive Officer of MicroPort Scientific Corporation ("**MPSC**") (a controlling shareholder of the Company and a company listed on The Stock Exchange of Hong Kong Limited with stock code: 00853). He is primarily responsible for expanding MPSC's international business in markets of the United States, Europe, Asia-Pacific and South America. Mr. Chen previously served as the Executive Vice President of International Operations and Investor Relations of MPSC, and also currently holds directorships in certain subsidiaries of MPSC. Mr. Chen served as the chairman and a director of Shanghai MicroPort Endovascular MedTech Co., Ltd., (a company listed on the Shanghai Stock Exchange with stock code: 688016) from 2023 to 2025. Prior to joining MPSC, Mr. Chen successively served as the vice president and senior vice president of business development and financial strategy at Angiotech Pharmaceuticals, Inc. Prior to joining Angiotech, Mr. Chen was a life sciences investment banker at Credit Suisse, Alex. Brown & Sons and Deutsche Bank, where he advised his clients on equity and debt financing as well as on mergers and acquisitions transactions. Mr. Chen holds a Bachelor of Arts degree in Economics and a Bachelor of Sciences degree with honours in Biological Sciences from Stanford University.

Mr. Chen (i) is interested in 2,677,360 underlying shares of MPSC by virtue of the share options granted to him under the share scheme(s) of MPSC; (ii) holds 743,757 shares of MPSC through his wholly-owned company; and (iii) is interested in the convertible bonds issued by MPSC with a principal amount of US$500,000 held by his wholly-owned company (which are convertible into a total of 305,767 conversion shares based on the initial conversion price). In addition, Mr. Chen is interested in 56,036 underlying H shares of the Company.

Save as disclosed above, (i) Mr. Chen does not hold any other positions with the Company and/or any of its subsidiaries; (ii) Mr. Chen does not, nor did he in the past three years, hold any directorships in other public companies whose securities are listed on any securities market in Hong Kong or overseas; (iii) Mr. Chen does not have any relationships with any directors, supervisors, senior management, substantial shareholders or controlling shareholders of the Company; and (iv) Mr. Chen does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "**SFO**").

As at the date of this announcement, there are no other matters relating to the proposed appointment of Mr. Chen that are required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited ("**Listing Rules**"), and there are no other matters relating to the proposed appointment of Mr. Chen that need to be brought to the attention of the shareholders of the Company.

Ms. Qing Hui

The biographical details of Ms. Hui are as follows:

Ms. Hui, aged 56, is currently the First Vice President of Organization Ability of MPSC. Ms. Hui joined MPSC in 2019 and has been leading the core function of Organizational Ability in the headquarters since then. Prior to joining MPSC, she had worked for Boston Scientific for more than 12 years with various Human Resources leadership roles in different countries and regions including China, Asia Pacific, Middle East and Canada. Before that, she worked for banking and insurance industries for more than ten years. Ms. Hui received her bachelor's degree in English from Shanghai Polytechnic University in 1992, master's degree in Business Administration from Shanghai University of Finance and Economic in 2002 and executive master's degree in Consulting and Coaching for Change from Institut Europeen d'Administration des Affaires in 2017.

Ms. Hui (i) is interested in 1,809,779 underlying shares of MPSC by virtue of the share options granted to her under the share scheme(s) of MPSC; and (ii) holds 213,454 shares of MPSC.

Save as disclosed above, (i) Ms. Hui does not hold any other positions with the Company and/or any of its subsidiaries; (ii) Ms. Hui does not, nor did she in the past three years, hold any directorships in other public companies whose securities are listed on any securities market in Hong Kong or overseas; (iii) Ms. Hui does not have any relationships with any directors, supervisors, senior management, substantial shareholders or controlling shareholders of the Company; and (iv) Ms. Hui does not have any interest in the shares of the Company within the meaning of Part XV of the SFO.

As at the date of this announcement, there are no other matters relating to the proposed appointment of Ms. Hui that are required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules, and there are no other matters relating to the proposed appointment of Ms. Hui that need to be brought to the attention of the shareholders of the Company.

Upon the proposed appointments of Mr. Chen and Ms. Hui being approved by the shareholders of the Company, they will enter into letters of appointment with the Company for a term of not more than three years commencing from the date of being elected at the EGM until the end of the Board's session. Pursuant to the letters of appointment, Mr. Chen and Ms. Hui will not receive any remuneration from the Group for their positions as non-executive directors.

A circular, containing details of, among other things, the proposed appointments of Mr. Chen and Ms. Hui as non-executive directors of the Company will be despatched to the shareholders of the Company in due course.

By order of the Board
Shanghai MicroPort MedBot (Group) Co., Ltd.
Dr. Zhaohua Chang
Chairman

Shanghai, China, 27 August 2026

As at the date of this announcement, the executive director is Dr. Chao He, the non-executive directors are Dr. Zhaohua Chang, Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida, Mr. Chen Chen and Ms. Min Liang, and the independent non-executive directors are Dr. Guoen Liu, Mr. Jonathan H. Chou, Mr. Haisong Yao and Mr. Wai Man Chung.